<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; ISPH</title>
	<atom:link href="http://www.stockbloghub.com/tag/isph/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ISPH) Inspire Pharmaceuticals, Inc. &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2009/11/09/isph-inspire-pharmaceuticals-inc-bull-of-the-day/20018</link>
		<comments>http://www.stockbloghub.com/2009/11/09/isph-inspire-pharmaceuticals-inc-bull-of-the-day/20018#comments</comments>
		<pubDate>Mon, 09 Nov 2009 23:23:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Inspire Pharmaceuticals Inc]]></category>
		<category><![CDATA[ISPH]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20018</guid>
		<description><![CDATA[Inspire Pharmaceuticals, Inc. (ISPH) is a specialty pharmaceutical company focused on the development and commercialization of treatments for respiratory and ophthalmologic disorders. Currently, the company has three products on the market and a robust pipeline. We see strong top line growth from 2009 and beyond. Inspire just reported positive phase III data of Denufosol for CF. The company has a strong collaborative alliance with Allergan Pharmaceuticals for key products that treat dry eyes and allergic conjunctivitis. Current price is attractive. We maintain our Outperform rating on shares of Inspire with a price target of $7.00. Zacks Investment Research View original at: Zacks.com News Feed]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/09/isph-inspire-pharmaceuticals-inc-bull-of-the-day/20018/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

